Ahead of merger with Pfizer's generic unit, Mylan makes $757M+ purchase for European thrombosis portfolio

Mylan is increasing its presence in Europe with a high-dollar acquisition of a blood clot portfolio.

The generic drugmaker is paying more than three-quarters of a billion dollars to gobble up Aspen Pharmacare’s thrombosis business on the continent. The exact sum of €641.9 million, or about $757 million, will be divvied up into an upfront payment of about 41% of the total, with the remaining being deferred to next June.